AXA Framlington Biotech Z Inc (FUND:BRJZVL2) - Fund price - Overview

Fund Report

AXA Framlington Biotech Fund Z INC

Key Stats
Morningstar® CategorySector Equity Biotechnology
Manager NameLinden Thomson
Inception Date19/01/2015
NAV 25/05/2018GBX 116.20
Day Change0.61%
12 Month Yield0.00%
ISINGB00BRJZVL27
SEDOLBRJZVL2
Dividend FrequencySemi-Annually
Net Assets (mil) 30/04/2018478.44 GBP
Wrapper AvailabilityAll
Our Minimum Initial Investment1.00 Share
Pricing FrequencyDaily
Dealing Cut off Time10:30:00
Regular InvestmentYes
Actual Initial Charge0.00%
Exit Charge-
Custody ChargeYes
Ongoing Cost0.83%
AMC0.75%
Fund Rebate-

Morningstar Rating™

4 Stars

Morningstar Sustainability Rating

Above Average

Above Average


Sustainability Rating as of 31/03/2018

Benchmarks

Fund Benchmark

NASDAQ Biotechnology TR USD

Morningstar® Benchmark

MSCI World/Biotechnology NR USD

Growth Of 10,000 (GBP) 30/04/2018

How has this security performed
201320142015201620172018
Fund63.7145.1812.26-4.969.642.75
Category55.0438.5413.41-3.9610.29-3.59
Benchmark64.6138.9313.904.787.96-5.21
  • Fund: AXA Framlington Biotech Fund Z INC
  • Category: Sector Equity Biotechnology
  • Benchmark: MSCI World/Biotechnology NR USD
Trailing Returns % (GBP) 25/05/2018
FundCatBmark
YTD6.412.05-0.85
3 Years Annualised1.201.784.10
5 Years Annualised15.8814.0514.62
10 Years Annualised18.7717.9920.11

Morningstar SRRI

Lower Risk
Higher Risk
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Potentially Lower ReturnsPotentially Higher Returns
Source: Morningstar

Investment Objective

The objective is to provide long-term capital appreciation by investing principally in equity securities of companies in biotechnology, genomic and medical research industries worldwide.

Portfolio Profile30/04/2018

Morningstar Style Box®

Equity Style

Large, Mid, SmallSize
Value, Blend, Growth
Style
Top Holdings
NameSector%
IncreaseDecreaseNew since last portfolio
IncreaseBiogen Inc Healthcare9.88
IncreaseCelgene Corp Healthcare7.04
IncreaseAlexion Pharmaceuticals Inc Healthcare6.71
IncreaseGilead Sciences Inc Healthcare5.44
IncreaseRegeneron Pharmaceuticals Inc Healthcare4.36
Asset Allocation %
LongShortNet
Stocks96.350.0096.35
Bonds0.000.000.00
Cash3.881.252.63
Other1.010.001.01
Top Stock Regions
Region%
United States88.52
United Kingdom4.78
Eurozone4.46
Europe - ex Euro1.74
Canada0.51
Top Stock Sectors
Stock Sector%
Healthcare100.00
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2018 Morningstar. All rights reserved.